Today, the Food and Drug Administration (FDA) announced additional labeling changes for menopausal hormone therapy (MHT) products and outlined efforts to expand access to treatment. The announcement builds on the FDA’s February 2026 labeling actions and supports President Trump’s October 19 Executive Order, Advancing Women’s Health to Improve Outcomes in All Phases of Life. It also comes amid broader federal attention… (Eisen, October 30, 2026) #Food and Drug Administration, #Prescription Drugs, #Women’s Health